Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCRT and Sorafenib Sequential Therapy in Advanced HCC
NCT02425605Phase 2
Key facts
- Status
- Completed
- Start
- Dec 2014
- Primary completion
- Sep 2017
- Countries
- 1
- Sponsor
- Yonsei University
- Modality
- Small Molecules
- Drugs
- sorafenib
- Conditions
- hepatocellular carcinoma (HCC)
01
Overview
Phase 2, open-label, single-arm trial of sorafenib in hepatocellular carcinoma (HCC), sponsored by Yonsei University. Primary endpoint: Overall Survival at 36 months. Started Dec 2014; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
CCRT-sorafenib group
CCRT followed by Sorafenib
03
Endpoints
Primary
Overall Survival
Secondary
Progression-Free Survival (Liver)
Progression-Free Survival (Overall)
Tumor Response
Toxicity
Beyond the preview
Go deeper on NCT02425605.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02425605.